HRT and cardiovascular events

Authors’ reply to Marjoribanks and colleagues, Rossouw and colleagues, Schroll and Lundh, and McPherson

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8164 (Published 3 December 2012)
Cite this as: BMJ 2012;345:e8164

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Louise Lind Schierbeck, registrar1,
  2. Lars Køber, professor, consultant2,
  3. Jens-Erik Beck Jensen, associate professor, consultant1
  1. 1Department of Endocrinology, Hvidovre Hospital, 2650 Hvidovre, Denmark
  2. 2Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
  1. louise.schierbeck{at}gmail.com

We are grateful for all of the interest in our paper1; more extensive answers are available at bmj.com (www.bmj.com/content/345/bmj.e6409/rr/612351).

Although randomisation is an important part of any trial, we acknowledge that performance and detection bias exist in open label trials,2 3 but these biases are less important when endpoints are driven by mortality. Furthermore, no trial of hormone replacement therapy (HRT)—including the Women’s Health Initiative—conducted in women with a uterus is completely blinded.4 5 …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL